Clinical Trial Update: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) [Phase 3]

View source ↗

Summary

A Phase 3 trial is comparing depemokimab with mepolizumab in adults with eosinophilic granulomatosis with polyangiitis, with ongoing assessment of efficacy and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• Depemokimab (depemokimab)
• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING